Biotechnology recruiting is hot. It''s more active than IT and telecommunications and it isn''t suffering the shortages in other areas of healthcare, says Frank Heasley, PhD, President and CEO, of ...

Investors Should Know: The GLP-1 and broader metabolic disease drug space is advancing rapidly, with next-generation oral formulations, triple-acting compounds, and combination therapies moving ...

Fintel reports that on August 11, 2023, HC Wainwright & Co. reiterated coverage of IO Biotech (NASDAQ:IOBT) with a Buy recommendation. As of August 2, 2023, the average one-year price target for IO ...